The 23 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 252.00, with a high estimate of 415.00 and a low estimate of 143.00. The median estimate represents a +7.98% increase from the last price of 233.37.
The current consensus among 26 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.85
Reporting Date Feb 23
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.